NovoCure (NVCR) Debt to Equity (2016 - 2025)
Historic Debt to Equity for NovoCure (NVCR) over the last 11 years, with Q3 2025 value amounting to $0.57.
- NovoCure's Debt to Equity rose 11176.63% to $0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.57, marking a year-over-year increase of 11176.63%. This contributed to the annual value of $0.27 for FY2024, which is N/A changed from last year.
- Per NovoCure's latest filing, its Debt to Equity stood at $0.57 for Q3 2025, which was up 11176.63% from $0.28 recorded in Q2 2025.
- In the past 5 years, NovoCure's Debt to Equity ranged from a high of $1.59 in Q1 2024 and a low of $0.27 during Q2 2024
- Moreover, its 5-year median value for Debt to Equity was $1.29 (2022), whereas its average is $1.02.
- Per our database at Business Quant, NovoCure's Debt to Equity soared by 15276.89% in 2021 and then plummeted by 8301.61% in 2025.
- NovoCure's Debt to Equity (Quarter) stood at $1.37 in 2021, then fell by 6.41% to $1.28 in 2022, then rose by 12.55% to $1.44 in 2023, then tumbled by 81.27% to $0.27 in 2024, then skyrocketed by 111.08% to $0.57 in 2025.
- Its Debt to Equity stands at $0.57 for Q3 2025, versus $0.28 for Q2 2025 and $0.27 for Q1 2025.